The Global Epilepsy Market, Pipeline and Competition 2020-2030 - Aquestive Therapeutical's AQST-203 Will Be a Blockbuster Drug
DUBLIN, March 9, 2020 /PRNewswire/ -- The "Epilepsy - Competitive Landscape, Market and Pipeline Analysis, 2020" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The future competitive landscape of Epilepsy is estimated to be very strong. Key emerging drugs including Aquestive Therapeutical's AQST-203 and others are going to be Blockbuster in the upcoming years.
Epilepsy - Competitive Landscape, Market and Pipeline Analysis, 2020 provides comprehensive insights on the therapeutic development for this mechanism of action. The objective of the report is to establish an understanding of the therapeutic competitive landscape for Epilepsy, including the marketed and pipeline products in this space.
The report provides detailed information on marketed products with historical and forecasted sales till 2030. It further offers comparative pipeline analysis with their drug profiles at various stages of development covering Phase III, Phase II, Phase I, Preclinical and Discovery. Information on company collaborations, agreements, acquisitions, licensing, deals, and other development activities is also involved in this report.
Therapeutics assessment of active pipeline drugs by stage, therapy type, route of administration, and molecule type is also covered in this report. It features the inactive pipeline products and highlights currently undergoing institutional research in this area. The report provides the understanding of the unmet needs, market drivers and barriers of the Epilepsy market.
This report on Epilepsy helps companies in understanding market dynamics based on this mechanism of action and therefore giving opportunities for a strategic alliance that will result in market penetration and enhancement of portfolios with optimal investment and maximal return. In addition s will assuage companies to detect conditions, determine genetic predisposition and biological response to Epilepsy.
The report provides insights into:
-- Detailed market drug profiles available in the market indicated for this
mechanism of action with historical and forecasted sales till 2030.
-- A number of companies developing therapies of Epilepsy with aggregate
therapies developed by each company for the same.
-- Detailed profiles of therapeutic candidates in nonclinical stage,
early-stage, mid-stage and late-stage of development for Epilepsy.
-- Analyses key players involved in Epilepsy targeted therapeutics
development with respective active and inactive (dormant or
discontinued) projects.
-- Active pipeline therapies assessment under development based on the
stage of development, route of administration, target receptor,
monotherapy or combination therapy, a different mechanism of action, and
molecular type.
-- Detail analysis of collaboration (company-company collaborations and
company-academia collaborations), licensing agreement and financing
details for future developments of Epilepsy.
Scope of the Report
-- The Epilepsy report provides an overview of this mechanism of action,
role, significance, pathway, types, and clinical application of IDH
inhibitors.
-- Therapeutic Assessment: Therapeutic pipeline activity and assessment of
the products by development stage, product type, route of
administration, molecule type, and MOA the complete product development
cycle, including all clinical and nonclinical stages.
-- It comprises of detailed profiles of therapeutic products for Epilepsy
with key coverage of developmental activities, including collaborations,
agreements, licensing, mergers and acquisition, funding, designations,
technology and other product-related details.
-- In-depth Epilepsy research and development progress and trial details
results wherever available, are also included in the pipeline study.
-- Coverage of dormant and discontinued pipeline projects along with the
reasons if available across Epilepsy.
-- The report has also covered the worldwide market of Epilepsy,
information of marketed therapies, their historical and forecasted sales
till 2030.
-- It also includes patent expiry details impact on market after expiry.
-- Key topics covered include strategic competitor assessment, market
characterization, opportunities, unmet needs, market growth factors,
barriers and challenges along with SWOT analysis of the Epilepsy market.
-- Analysis of the current and future market competition in the global
Epilepsy market. Current scenario of the market with upcoming
blockbuster molecules and their impact on the overall market.
Report Highlights
-- In the coming years, the Epilepsy market is set to change due to the
extensive research in this filed, and incremental healthcare spending
across the world; which would expand the size of the market to enable
the drug manufacturers to penetrate more into the market.
-- The companies and academics are working to assess challenges and seek
opportunities that could influence Epilepsy R&D. The Epilepsy therapies
under development are focused on novel approaches to treat/improve the
disease condition.
-- There are many companies involved in developing therapies for Epilepsy.
Launch of emerging therapies of Epilepsy will significantly impact the
market.
-- A better understanding of the target mechanism will also contribute to
the development of novel therapeutics for Epilepsy.
-- In-depth analysis of the pipeline assets (in early-stage, mid-stage and
late-stage of development for the treatment of Epilepsy includes
therapeutic assessment and comparative analysis. This will support the
clients in the decision-making process regarding their therapeutic
portfolio by identifying the overall scenario of the research and
development activities.
-- The report provides the detailed analysis of 100+ products along with
40+ companies involved
Companies Mentioned
-- Supernus Pharmaceuticals
-- Lundbeck
-- Greenwich Biosciences
-- Eisai
-- UCB
-- Pfizer
-- Aquestive Therapeutics
-- and many more...
Key Questions
-- What are Epilepsy, their role and significance in the treatment of
disease conditions?
-- What are the current treatment options based on the Epilepsy available
in the market?
-- How the historical and forecasted sales of the marketed therapies
determine their scenario in the current Epilepsy market?
-- How many therapies are developed by each company for Epilepsy to treat
disease conditions?
-- What are the key collaborations (Industry-Industry, Industry-Academia),
mergers and acquisitions, licensing activities related to the Epilepsy
therapies?
-- Which are the dormant and discontinued products and the reasons for
dormancy and discontinuation?
-- What is the unmet need for current therapies developed on the basis of
this mechanism of action?
-- What are the recent novel therapies, targets, mechanisms of action and
technologies developed to overcome the limitation of existing therapies?
-- What are the clinical studies going on for Epilepsy and their status?
For more information about this report visit https://www.researchandmarkets.com/r/uax9kq
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/the-global-epilepsy-market-pipeline-and-competition-2020-2030---aquestive-therapeuticals-aqst-203-will-be-a-blockbuster-drug-301019770.html
SOURCE Research and Markets
